Kristen M Marks

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. doi request reprint The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir
    Kristen M Marks
    Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Antivir Ther 17:1119-31. 2012
  2. pmc Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy
    Kristen M Marks
    Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 52:595-9. 2009
  3. pmc Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239
    Kristen M Marks
    Division of Infectious Diseases, Weill Cornell Medical College, New York, NY Harvard School of Public Health, Boston, MA Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Division of Infectious Diseases, University of California San Francisco Medical School, San Francisco, CA Medical Service, Department of Veterans Affairs, San Francisco, CA and HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA
    J Acquir Immune Defic Syndr 65:345-9. 2014
  4. pmc Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection
    Daniel S Fierer
    Divisions of Infectious Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Clin Infect Dis 56:1038-43. 2013
  5. ncbi request reprint Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus
    Kristen M Marks
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 192:1943-9. 2005
  6. pmc Identification of substance use and dependence among patients with viral hepatitis
    Colin B Jackson
    The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA
    Dig Liver Dis 42:650-6. 2010

Collaborators

Detail Information

Publications6

  1. doi request reprint The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir
    Kristen M Marks
    Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Antivir Ther 17:1119-31. 2012
    ..This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions...
  2. pmc Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy
    Kristen M Marks
    Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 52:595-9. 2009
    ..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV...
  3. pmc Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239
    Kristen M Marks
    Division of Infectious Diseases, Weill Cornell Medical College, New York, NY Harvard School of Public Health, Boston, MA Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Division of Infectious Diseases, University of California San Francisco Medical School, San Francisco, CA Medical Service, Department of Veterans Affairs, San Francisco, CA and HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA
    J Acquir Immune Defic Syndr 65:345-9. 2014
    ..29, lower limit of the exact 1-sided 90% confidence interval 5.9%). Over the 24 weeks of PIO monotherapy, alanine aminotransferase and aspartate aminotransferase declined significantly and correlated with improved metabolic parameters. ..
  4. pmc Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection
    Daniel S Fierer
    Divisions of Infectious Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Clin Infect Dis 56:1038-43. 2013
    ....
  5. ncbi request reprint Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus
    Kristen M Marks
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 192:1943-9. 2005
    ..The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized...
  6. pmc Identification of substance use and dependence among patients with viral hepatitis
    Colin B Jackson
    The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA
    Dig Liver Dis 42:650-6. 2010
    ..As drug abuse and addiction have been shown to decrease adherence to treatment of hepatitis C virus (HCV) or HIV, screening for substance use should be standard clinical practice in those undergoing an evaluation for these diseases...